Dublin, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The "Infertility Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Infertility Drugs was estimated at US$4.9 Billion in 2023 and is projected to reach US$7.0 Billion by 2030, growing at a CAGR of 5.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Infertility drugs are medications used to treat reproductive problems in both men and women to increase their chances of conceiving. These drugs generally work by regulating or stimulating ovulation, enhancing sperm production, or correcting hormonal imbalances. In women, common treatments include drugs like Clomiphene citrate, Gonadotropins, and Metformin, which are used to trigger the release of eggs from the ovaries.
For men, medications may improve sperm count and quality. The development and use of these drugs are critical as infertility rates have been rising globally, driven by factors such as delayed childbearing, lifestyle changes, and increased prevalence of conditions like polycystic ovary syndrome (PCOS) and endometriosis.
How Are Advances in Medical Research Shaping the Infertility Drugs Market?
The infertility drugs market is continuously shaped by advances in medical research and biotechnology, including the development of more targeted hormone treatments and the introduction of new drug classes. Innovations such as the use of artificial intelligence (AI) to personalize drug protocols based on individual patient responses are enhancing the efficacy and success rates of these treatments. Furthermore, ongoing research into the genetic factors underlying infertility is opening up possibilities for genomic therapies that could correct genetic defects causing reproductive issues. Such advancements not only promise to increase the effectiveness of existing drugs but also help in developing novel therapies with fewer side effects.
What Trends Are Influencing the Demand for Infertility Drugs?
Several trends are currently influencing the demand for infertility drugs. Social trends, including the increasing age of first-time parents, contribute significantly to rising infertility rates, thereby driving the need for effective pharmacological interventions. The growing public awareness and acceptance of fertility treatments, coupled with improvements in healthcare infrastructure, are making these drugs more accessible to a broader population. Moreover, health insurance providers are gradually recognizing the need for comprehensive reproductive health services, including coverage for infertility treatments, which is making these drugs more affordable and further stimulating market growth.
Growth in the Infertility Drugs Market Is Driven by Several Factors
The growth in the infertility drugs market is driven by several factors related to advancements in medical science, changes in socio-economic conditions, and evolving consumer behaviors. Technological progress in drug development and the application of precision medicine are significantly enhancing the effectiveness and reducing the risks associated with infertility treatments. Economic factors, such as increased healthcare spending and the inclusion of fertility treatments in insurance coverage, are making these drugs more accessible and affordable. Additionally, global changes in attitudes towards fertility and an increase in the number of fertility clinics are expanding the consumer base for these drugs. Together, these dynamics are propelling robust growth in the infertility drugs market, reflecting a combination of improved treatment options and broader societal acceptance of fertility issues.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Hormone-Based Therapy segment, which is expected to reach US$5.3 Billion by 2030 with a CAGR of a 5.6%. The Other Products segment is also set to grow at 4.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, which was estimated at $1.3 Billion in 2023, and China, forecasted to grow at an impressive 8.1% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Abbott Laboratories, AbbVie Inc., Allergan Plc, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 193 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $4.9 Billion |
| Forecasted Market Value (USD) by 2030 | $7 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- Infertility Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Global Economic Update
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Rising Global Incidence of Infertility Spurs Demand for Advanced Fertility Treatments
- Growing Awareness of Reproductive Health Throws Spotlight on Infertility Drug Market Expansion
- Advancements in Assisted Reproductive Technologies (ART) Propel Growth in Infertility Drug Use
- Increasing Age of First-Time Parenthood Expands Addressable Market for Infertility Drugs
- Stringent Regulatory Approvals and Guidelines Drive Adoption of Clinically-Validated Infertility Medications
- Demand for Personalized Medicine Strengthens Business Case for Tailored Infertility Treatments
- Rising Incidence of Polycystic Ovary Syndrome (PCOS) and Other Reproductive Disorders Drives Drug Demand
- Innovation in Hormonal Therapies Generates New Opportunities in Infertility Drug Development
- Impact of Lifestyle Factors, Such as Stress and Obesity, on Fertility Propels Demand for Therapeutic Solutions
- Increasing Investment in Fertility Clinics and Specialized Healthcare Facilities Expands Market for Infertility Drugs
- Growing Use of Combination Therapies in Fertility Treatments Sustains Market Growth
FOCUS ON SELECT PLAYERS(Total 44 Featured)
- Abbott Laboratories
- AbbVie Inc.
- Allergan Plc
- Bayer AG
- Eli Lilly
- F. Hoffmann-La Roche Ltd
- Ferring Pharmaceuticals AS
- GlaxoSmithKline Plc
- LIVZON Pharmaceutical Group Inc.
- Merck & Co. Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Zydus Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/mx222z
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
